-transparent.png){kind=logo}
Two monoclonal antibodies (mAb), termed ED6 and LD6, were obtained by immunizing mice with cytotoxic T cell lines expressing the T cell receptor (TcR) gamma/delta. These mAb were selected according to their ability to trigger the cytolytic program of the immunizing cell lines in a redirected killing assay. Both mAb recognized molecule(s) expressed on the surface of most long-term cultured TcR gamma/delta +, TcR alpha/beta + and CD3-CD16+ lymphocytes, while it was absent on resting peripheral blood lymphocytes. In addition both mAb reacted with neoplastic B cell lines, Epstein-Barr virus-transformed B cell lines, small cell lung cancer and glioma cell lines, while no surface reactivity was detected on ovarian, breast, colon and non-small cell lung cancer lines. The functional activity of these mAb was studied by two cytolytic assays. Both mAb were able to trigger the cytolytic program of CD3+TcR gamma/delta + polyclonal cell lines and of a CD3-CD16+ NK cell clone against the murine mastocytoma target cell line P815 (Fc receptor+) in a 4-h 51Cr-release assay. In addition, ED6 and LD6 hybridomas were lysed by TcR gamma/delta + effector cells while other hybridomas (obtained from the same fusion) were not lysed. ED6 and LD6 mAb (in the presence of submitogenic doses of the phorbol 12-myristate 13-acetate) also induced the secretion of interleukin 2 by ED6/LD6+ T cell clones expressing TcR gamma/delta or alpha/beta. mAb-induced surface antigen modulation experiments showed that the antigenic determinant recognized by ED6 and LD6 co-modulated, thus indicating that the two mAb probably recognize the same or closely associated molecules. The molecular characteristics of the antigen recognized by the mAb were investigated by Western blot analysis. The LD6 mAb recognized a major band of approximately 65 kDa, both under nonreducing and reducing conditions. These data indicate that ED6 and LD6 mAb recognize a novel non-lineage-specific activation antigen which is involved in the induction of the functional program of long-term cultured T or natural killer cells.
S Ferrini, and
C Cantoni, and
E Ciccone, and
R Biassoni, and
I Prigione, and
C Bottino, and
P Venzano, and
L Moretta
June 1998,
The Journal of experimental medicine,
S Ferrini, and
C Cantoni, and
E Ciccone, and
R Biassoni, and
I Prigione, and
C Bottino, and
P Venzano, and
L Moretta
November 1989,
European journal of immunology,
S Ferrini, and
C Cantoni, and
E Ciccone, and
R Biassoni, and
I Prigione, and
C Bottino, and
P Venzano, and
L Moretta
October 1997,
The Journal of experimental medicine,
S Ferrini, and
C Cantoni, and
E Ciccone, and
R Biassoni, and
I Prigione, and
C Bottino, and
P Venzano, and
L Moretta
February 1990,
Journal of immunology (Baltimore, Md. : 1950),
S Ferrini, and
C Cantoni, and
E Ciccone, and
R Biassoni, and
I Prigione, and
C Bottino, and
P Venzano, and
L Moretta
July 1991,
Journal of immunology (Baltimore, Md. : 1950),
S Ferrini, and
C Cantoni, and
E Ciccone, and
R Biassoni, and
I Prigione, and
C Bottino, and
P Venzano, and
L Moretta
January 1999,
Microbiology and immunology,
S Ferrini, and
C Cantoni, and
E Ciccone, and
R Biassoni, and
I Prigione, and
C Bottino, and
P Venzano, and
L Moretta
January 1992,
Journal of immunology (Baltimore, Md. : 1950),
S Ferrini, and
C Cantoni, and
E Ciccone, and
R Biassoni, and
I Prigione, and
C Bottino, and
P Venzano, and
L Moretta
March 1992,
Scandinavian journal of immunology,
S Ferrini, and
C Cantoni, and
E Ciccone, and
R Biassoni, and
I Prigione, and
C Bottino, and
P Venzano, and
L Moretta
March 1990,
The Journal of experimental medicine,
S Ferrini, and
C Cantoni, and
E Ciccone, and
R Biassoni, and
I Prigione, and
C Bottino, and
P Venzano, and
L Moretta
February 1991,
Cytotechnology,
